Bacterial Meningitis in Childhood Can Devastate the Lives of Survivors
By Ernie Mundell HealthDay Reporter
MONDAY, Jan. 22, 2024 -- Infection in childhood with bacterial meningitis leaves one-third of survivors with long-term neurological damage, often severe, a new study shows.
The disease is rare and easily treated with antibiotics. However, as Swedish researchers point out, antibiotics take time to penetrate the brain's protective barrier.
That leaves time for the Streptococcus pneumoniae bacterium, which typically causes meningitis, to wreak havoc on nerve cells.
Comparing the 23-year outcomes of 3,500 people who battled bacterial meningitis in childhood to those of 32,000 people from the general population, the researchers found much higher rates of long-term neurological issues among survivors of the disease.
These included serious conditions such as cognitive impairment, seizures, visual or hearing impairment, motor impairment, behavioral disorders or structural damage to the head.
“This shows that even if the bacterial infection is cured, many people suffer from neurological impairment afterwards,” said study co-author Federico Iovino. He's associate professor in medical microbiology at the Karolinska Institute in Stockholm.
Compared to people who hadn't had bacterial meningitis, survivors faced 26 times the odds for structural damage to the head, an eight-fold higher risk for impaired hearing, and five times the odds for motor impairments, the research showed.
The long-term damage stemming from bacterial meningitis can be profound.
"When children are affected, the whole family is affected," Iovino explained in an institute news release. "If a three-year-old child has impaired cognition, a motor disability, impaired or lost vision or hearing, it has a major impact. These are lifelong disabilities that become a major burden for both the individual and society, as those affected need health care support for the rest of their lives."
His team is involved in research to help prevent these tragedies.
“We are trying to develop treatments that can protect neurons in the brain during the window of a few days it takes for antibiotics to take full effect," Iovino explained. "We now have very promising data from human neurons and are just entering a preclinical phase with animal models. Eventually, we hope to present this in the clinic within the next few years."
The study was funded by drug company Merck and published Jan. 19 in JAMA Network Open.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-01-23 04:15
Read more
- New Combo Drug Therapy Halves Death Risk From Advanced Hodgkin Lymphoma
- Better Prepared Emergency Departments Could Save Children's Lives
- FDA Approves Aucatzyl (obecabtagene autoleucel) for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
- The Right Time is Now to Get Your Flu Vaccine
- CDC Says Some People May Need Extra Dose of COVID Vaccine
- Protega Pharmaceuticals Receives FDA Approval for RoxyBond (oxycodone hydrochloride) Immediate-Release 10 mg Tablet with Abuse-Deterrent Technology for Management of Pain
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions